In that study, data from six PD-GBA1 patients were available only after 5 years; however, the mean decline in MDRS-2 scores for PD-GBA1 was 4.4 points per year compared with 0.5 points per year among non-GBA1 carriers. This evidence concerns the gene GBA1 and Parkinson disease.